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Background
The cardiovascular safety and efficacy of many current antihyperglycemic agents, 
including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
Methods
We randomly assigned 16,492 patients with type 2 diabetes who had a history of, 
or were at risk for, cardiovascular events to receive saxagliptin or placebo and fol-
lowed them for a median of 2.1 years. Physicians were permitted to adjust other 
medications, including antihyperglycemic agents. The primary end point was a 
composite of cardiovascular death, myocardial infarction, or ischemic stroke.
Results
A primary end-point event occurred in 613 patients in the saxagliptin group and in 
609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year 
Kaplan–Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence inter-
val [CI], 0.89 to 1.12; P = 0.99 for superiority; P<0.001 for noninferiority); the results 
were similar in the “on-treatment” analysis (hazard ratio, 1.03; 95% CI, 0.91 to 
1.17). The major secondary end point of a composite of cardiovascular death, myo-
cardial infarction, stroke, hospitalization for unstable angina, coronary revascular-
ization, or heart failure occurred in 1059 patients in the saxagliptin group and in 
1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 
2-year Kaplan–Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P = 0.66). 
More patients in the saxagliptin group than in the placebo group were hospitalized 
for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P = 0.007). 
Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two 
groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo 
group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively).
Conclusions
DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic 
events, though the rate of hospitalization for heart failure was increased. Although 
saxagliptin improves glycemic control, other approaches are necessary to reduce 
cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-
Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.)
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Type 2 diabetes mellitus doubles the risk of major cardiovascular complications in patients with and in patients without 
established cardiovascular disease,1-3 such that the 
majority of patients with diabetes die of cardio-
vascular diseases.4 Although improved glycemic 
control has repeatedly been shown to reduce mi-
crovascular diabetic complications,5 uncertainty 
remains regarding whether any particular glucose-
lowering strategy, or specific therapeutic agent, is 
safe from a cardiovascular standpoint or can ac-
tually lower cardiovascular risk. With the possi-
ble exception of trials of metformin6 and insu-
lin,7 most reported trials to date evaluating the 
effects on cardiovascular outcomes of specific 
glucose-lowering strategies or medications either 
have been insufficiently powered or have shown 
no significant cardiovascular benefit8-10 or an in-
creased risk of death11 or heart failure.12-15 Thus, 
there remains a strong clinical need to identify 
antihyperglycemic agents that are, at a minimum, 
safe and that can potentially reduce cardiovascular 
complications. Moreover, in 2008, the Food and 
Drug Administration and the European Medicines 
Agency simultaneously revised their approval 
processes for all new glucose-lowering therapies 
to require a demonstration of cardiovascular 
safety.16
Saxagliptin (Onglyza, AstraZeneca and Bristol-
Myers Squibb) is a selective dipeptidyl peptidase 4 
(DPP-4) inhibitor.17 In phase 2–3 studies, treat-
ment with saxagliptin improved glycemic control 
as compared with placebo and in pooled analyses 
reduced the risk of major cardiovascular events.18 
The Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients with Diabetes Mel-
litus (SAVOR)–Thrombolysis in Myocardial In-
farction (TIMI) 53 trial was designed to evaluate 
the safety and efficacy of saxagliptin with respect 
to cardiovascular outcomes in patients with dia-
betes mellitus who are at risk for cardiovascular 
events.
Me thods
Study Oversight
SAVOR-TIMI 53 was a multicenter, randomized, 
double-blind, placebo-controlled, phase 4 trial. We 
conducted the trial at 788 sites in 26 countries 
(see the Supplementary Appendix, available with 
the full text of this article at NEJM.org).19 The 
trial was sponsored by AstraZeneca and Bristol-
Myers Squibb and designed by the TIMI Study 
Group and Hadassah Medical Organization in 
conjunction with the sponsors, who provided 
monitoring support and donated the drug. The 
protocol was approved by the relevant ethics 
committees at all participating centers. The raw 
database was provided to the TIMI Study Group, 
which, independently of the sponsor, performed 
the data analyses under the direction of one of 
the academic authors according to a prespecified 
statistical analysis plan (see the study protocol, 
available at NEJM.org). The first two authors 
wrote the first draft of the manuscript, and the 
TIMI Study Group drafted subsequent versions 
and made the decision to submit the manuscript 
for publication. The members of the TIMI Study 
Group and Hadassah Medical Organization as-
sume responsibility for the accuracy and com-
pleteness of the data and all the analyses and for 
the fidelity of this report to the protocol.
Study Population
Eligible patients had a history of documented 
type 2 diabetes mellitus, a glycated hemoglobin 
level of 6.5% to 12.0%, and either a history of 
established cardiovascular disease or multiple 
risk factors for vascular disease. To meet the cri-
teria for established cardiovascular disease, pa-
tients had to be at least 40 years old and have a 
history of a clinical event associated with athero-
sclerosis involving the coronary, cerebrovascular, 
or peripheral vascular system. To meet the crite-
ria for the multiple risk factors, patients had to be 
at least 55 years of age (men) or 60 years of age 
(women) with at least one of the following addi-
tional risk factors: dyslipidemia, hypertension, or 
active smoking. Patients were ineligible if they 
were currently receiving or had received within 
the previous 6 months an incretin-based therapy 
or if they had end-stage renal disease and were 
undergoing long-term dialysis, had undergone a re-
nal transplantation, or had a serum creatinine 
level higher than 6.0 mg per deciliter (530 μmol 
per liter). The full eligibility criteria have been 
reported previously.19 Written informed consent 
was obtained from all patients.
Randomization and Study Treatment
Eligible patients were randomly assigned, in a 1:1 
ratio, to receive saxagliptin at a dose of 5 mg 
daily (or 2.5 mg daily in patients with an esti-
mated glomerular filtration rate [GFR] of ≤50 ml 
per minute) or matching placebo. Randomiza-
tion was performed by means of a central com-
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puterized telephone or Web-based system in 
blocks of 4, with stratification according to the 
qualifying cardiovascular disease state (estab-
lished cardiovascular disease vs. multiple risk 
factors only) and renal function (normal func-
tion or mild renal impairment [estimated GFR, 
>50 ml per minute] vs. moderate renal impair-
ment [estimated GFR, 30 to 50 ml per minute] vs. 
severe renal impairment [estimated GFR, <30 ml 
per minute]).
Saxagliptin or placebo was administered in a 
blinded fashion until the end of the follow-up 
period. Patients in whom renal impairment (an 
estimated GFR of ≤50 ml per minute) developed 
during the study period had a single dose adjust-
ment to 2.5 mg daily. All other therapy for the 
management of the patient’s diabetes and car-
diovascular disease — including adding, discon-
tinuing, or changing the dose of concomitant 
antihyperglycemic drugs — was at the discre-
tion of the responsible physician. Concomitant 
use of other DPP-4 inhibitors or glucagon-like 
peptide 1 agonists was not allowed.
End Points
The primary efficacy and safety end point was a 
composite of cardiovascular death, nonfatal 
myocardial infarction, or nonfatal ischemic 
stroke. The secondary efficacy end point includ-
ed the primary composite end point plus hospi-
talization for heart failure, coronary revascular-
ization, or unstable angina. Definitions of the 
end points, which are provided in the Supple-
mentary Appendix, were developed to be consis-
tent with the definitions in the Standardized 
Definitions for End Point Events in Cardiovascu-
lar Trials draft, which was created as an initiative 
of the Food and Drug Administration.20 Pancre-
atitis was classified as acute (definite or possible) 
or chronic.
A clinical events committee comprising spe-
cialists in cardiovascular and pancreatic medi-
cine, all of whom were unaware of the study-
group assignments, adjudicated all components 
of the primary composite and secondary efficacy 
end points and all cases of pancreatitis.
Episodes of hypoglycemia were reported by 
the investigators and were classified as major if 
the events required a third party to intervene 
actively and minor if the patients had symptoms 
but recovered without assistance within 30 min-
utes after ingestion of carbohydrates. Investigators 
also reported any documented blood glucose 
level lower than 54 mg per deciliter (3.0 mmol 
per liter), regardless of symptoms. Hypoglycemic 
events that required hospitalization were also 
classified separately.
Statistical Analysis
The primary safety and efficacy analyses were 
performed according to the intention-to-treat 
principle on data from all patients who under-
went randomization, with the use of a Cox pro-
portional-hazards model, with stratification ac-
cording to baseline renal-impairment category 
and baseline cardiovascular risk group and with 
treatment as a model term. One planned interim 
analysis of efficacy was performed before com-
pletion of the study; therefore, a P value of less 
than 0.049 was considered to indicate statistical 
significance for the primary analysis. The trial 
was designed as a superiority trial, with a closed 
testing hierarchy to preserve the alpha level that 
prespecified that a test for noninferiority with 
respect to the primary composite end point 
should be performed first and a test for superior-
ity performed thereafter. An on-treatment (modi-
fied intention-to-treat) analysis, which included 
events that occurred within 30 days after the last 
dose of study medication was administered, was 
performed as a sensitivity analysis. Further de-
tails of the statistical analysis have been reported 
previously19 and are presented in the Supplemen-
tary Appendix.
R esult s
Study Patients
From May 2010 through December 2011, a total 
of 16,492 patients underwent randomization. 
The median follow-up period was 2.1 years (in-
terquartile range, 1.8 to 2.3), and the maximum 
follow-up time was 2.9 years. The total observa-
tion time was 16,884 person-years in the saxa-
gliptin group and 16,761 person-years in the pla-
cebo group. Details of the study assignment and 
patient disposition are presented in Figure S1 in 
the Supplementary Appendix. The study drug 
was discontinued prematurely less frequently 
among patients assigned to saxagliptin than 
among patients assigned to placebo (1527 pa-
tients [18.4%] vs. 1705 patients [20.8%], P<0.001). 
A final vital status was assessed in 99.1% of 
the patients. A total of 28 patients were lost to 
follow-up. The baseline characteristics of the pa-
tients who underwent randomization, which were 
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reported previously21 and are shown in Table 1 
and Table S1 in the Supplementary Appendix, 
were well balanced between the two groups.
The fasting plasma glucose levels were sig-
nificantly lower in the saxagliptin group than in 
the placebo group at 2 years and at the end of 
the treatment period (P<0.001 for both compari-
sons), and glycated hemoglobin levels were sig-
nificantly lower in the saxagliptin group than 
in the placebo group at 1 year (7.6% vs. 7.9%), 
at 2 years (7.5% vs. 7.8%), and at the end of the 
treatment period (7.7% vs. 7.9%) (P<0.001 for all 
comparisons). Specifically, significantly more pa-
tients in the saxagliptin group than in the pla-
cebo group had a glycated hemoglobin level of 
less than 7% by the end of the treatment period 
(36.2% vs. 27.9%, P<0.001) (Table S2 in the Sup-
plementary Appendix). Fewer patients in the sax-
a gliptin group than in the placebo group required 
an increase in the dose of antihyperglycemic 
medication or the addition of a new antihypergly-
cemic medication (1938 patients [23.7% according 
to 2-year Kaplan–Meier estimates] vs. 2385 pa-
tients [29.3% according to 2-year Kaplan–Meier 
estimates]; hazard ratio with saxagliptin, 0.77; 
95% confidence interval [CI], 0.73 to 0.82; P<0.001) 
or the initiation of insulin therapy for more than 
3 months (454 patients [5.5% according to 2-year 
Kaplan–Meier estimates] vs. 634 patients [7.8% 
according to 2-year Kaplan–Meier estimates]; 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Saxagliptin  
(N = 8280)
Placebo 
(N = 8212)
Age
Mean — yr 65.1±8.5 65.0±8.6
≥75 yr — no. (%) 1169 (14.1) 1161 (14.1)
Female sex — no. (%) 2768 (33.4) 2687 (32.7)
White race — no. (%)† 6241 (75.4) 6166 (75.1)
Hispanic ethnic group — no. (%)† 1778 (21.5) 1763 (21.5)
Weight‡
Mean — kg 87.7±18.7 88.1±19.4
≥80 kg — no. (%) 5291 (63.9) 5265 (64.2)
Body-mass index§
Mean 31.1±5.5 31.2 ±5.7
≥30 — no. (%) 4446 (53.7) 4370 (53.4)
Duration of diabetes — yr¶
Median 10.3 10.3
Interquartile range 5.2–16.7 5.3–16.6
Established atherosclerotic disease — no. (%) 6494 (78.4) 6465 (78.7)
Hypertension — no. (%) 6725 (81.2) 6767 (82.4)
Dyslipidemia — no. (%) 5895 (71.2) 5844 (71.2)
Prior myocardial infarction — no. (%) 3147 (38.0) 3090 (37.6)
Prior heart failure — no. (%) 1056 (12.8) 1049 (12.8)
Prior coronary revascularization — no. (%) 3566 (43.1) 3557 (43.3)
Glycated hemoglobin‖
Mean — % 8.0±1.4 8.0±1.4
Distribution — no. (%)
<6.5% 590 (7.3) 673 (8.3)
6.5 to <7.0% 1442 (17.7) 1414 (17.5)
7.0 to <8.0% 2759 (33.9) 2657 (32.9)
8.0 to <9.0% 1577 (19.4) 1562 (19.4)
≥9% 1761 (21.7) 1764 (21.9)
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hazard ratio, 0.70; 95% CI, 0.62 to 0.79; P<0.001). 
(Table S1 in the Supplementary Appendix pro-
vides details on the actual medication use over 
time.) Patients treated with saxagliptin were 
significantly more likely than patients receiving 
placebo to have an improved albumin-to-creati-
nine ratio and less likely to have a worsening 
ratio (Table S3 in the Supplementary Appendix).
Cardiovascular End Points
A primary end-point event of cardiovascular 
death, nonfatal myocardial infarction, or nonfatal 
ischemic stroke occurred in 613 patients in 
the saxagliptin group (7.3%, according to 2-year 
Kap lan–Meier estimates; 3.7 per 100 person-years) 
and in 609 patients in the placebo group (7.2%, 
according to 2-year Kaplan–Meier estimates; 3.7 
per 100 person-years) (hazard ratio, 1.00; 95% 
CI, 0.89 to 1.12; P = 0.99 for superiority and 
P<0.001 for noninferiority) (Table 2 and Fig. 1A). 
Similar results were seen in the modified inten-
tion-to-treat (on-treatment) population (6.8% with 
saxagliptin vs. 6.4% with placebo, according to 
2-year Kaplan–Meier estimates; hazard ratio with 
saxagliptin, 1.03; 95% CI, 0.91 to 1.17; P = 0.60) 
(Table S5 in the Supplementary Appendix).
A major secondary end-point event of cardio-
vascular death, nonfatal myocardial infarction, 
nonfatal ischemic stroke, hospitalization for 
un stable angina, coronary revascularization, or 
heart failure occurred in 1059 patients in the 
saxagliptin group (12.8%, according to 2-year 
Kaplan–Meier estimates; 6.6 per 100 person-
years) and in 1034 patients in the placebo group 
(12.4%, according to 2-year Kaplan–Meier esti-
mates; 6.5 per 100 person-years) (hazard ratio, 
1.02; 95% CI, 0.94 to 1.11; P = 0.66) (Table 2 and 
Fig. 1B). Individual components of these compos-
ite end points are shown in Table 2. More patients 
in the saxagliptin group than in the placebo group 
were hospitalized for heart failure (3.5% vs. 2.8%, 
according to 2-year Kaplan–Meier estimates; haz-
ard ratio, 1.27; 95% CI, 1.07 to 1.51; P = 0.007).
The results of additional analyses of efficacy 
Table 1. (Continued.) 
Characteristic
Saxagliptin  
(N = 8280)
Placebo 
(N = 8212)
Fasting serum glucose — mg/dl** 156±56 157±57
Estimated glomerular filtration rate
Mean — ml/min 72.5±22.6 72.7±22.6
Distribution — no. (%)
<30 ml/min 172 (2.1) 164 (2.0)
30 to ≤50 ml/min 1122 (13.6) 1118 (13.6)
>50 ml/min 6986 (84.4) 6930 (84.4)
Albumin-to-creatinine ratio††
Median 1.8 1.9
Interquartile range 0.7–7.5 0.7–7.9
Distribution — no. (%)
 <3.4 4867 (61.5) 4829 (61.6)
3.4 to 33.9 2217 (28.0) 2209 (28.2)
>33.9  832 (10.5)  806 (10.3)
* Plus–minus values are means ±SD. There were no significant differences between the two groups in any of the charac-
teristics listed here with the exception of hypertension, for which P = 0.049. To convert the values for glucose to milli-
moles per liter, multiply by 0.05551.
† Race and ethnic group were self-reported.
‡ Data were available for 8277 patients in the saxagliptin group and 8197 in the placebo group.
§ Body-mass index is the weight in kilograms divided by the square of the height in meters. Data were available for 8273 pa-
tients in the saxagliptin group and 8190 in the placebo group.
¶ Data were available for 8270 patients in the saxagliptin group and 8207 in the placebo group.
‖ Data were available for 8129 patients in the saxagliptin group and 8070 in the placebo group.
** Data were available for 7892 patients in the saxagliptin group and 7805 in the placebo group.
†† Albumin was measured in milligrams, and creatinine was measured in millimoles. Data were available for 7916 patients 
in the saxagliptin group and 7844 in the placebo group.
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in prespecified subgroups, including subgroups 
defined according to status with respect to car-
diovascular risk and baseline renal function, are 
shown in Figures S2 and S3 in the Supplementary 
Appendix. The adjudicated causes of death are 
shown in Table S4 in the Supplementary Appendix.
Safety End Points
The prespecified safety end points are listed in 
Table 3. The numbers of patients with thrombo-
cytopenia, lymphocytopenia, infections, cancers, 
hypersensitivity or skin reactions, bone fractures, 
or liver abnormalities were similar in the saxa-
gliptin and placebo groups. Hospitalization for 
hypoglycemia occurred infrequently, and the rate 
was similar in the two groups: 0.6% according to 
2-year Kaplan–Meier estimates (53 patients) in 
the saxagliptin group and 0.5% according to 
2-year Kaplan–Meier estimates (43 patients) in 
the placebo group (hazard ratio with saxagliptin, 
1.22; 95% CI, 0.82 to 1.83; P = 0.33). However, 
significantly more patients in the saxagliptin 
group than in the placebo group reported at least 
one hypoglycemic event (1264 patients [15.3%] 
vs. 1104 patients [13.4%], P<0.001); major hypo-
glycemic events occurred in 177 patients (2.1%) 
in the saxagliptin group as compared with 140 
patients (1.7%) in the placebo group (P = 0.047), 
and minor hypoglycemic events in 1172 patients 
(14.2%) in the saxagliptin group, as compared 
with 1028 patients (12.5%) in the placebo group 
(P = 0.002). Pancreatitis occurred infrequently, and 
the number of patients with acute or chronic pan-
creatitis was similar in the two groups (24 patients 
[0.3%] in the saxagliptin group and 21 patients 
[0.3%] in the placebo group, P = 0.77). Definite or 
possible acute pancreatitis occurred in 22 patients 
(0.3%) in the saxagliptin group and in 16 patients 
(0.2%) in the placebo group (P = 0.42), definite 
acute pancreatitis in 17 patients (0.2%) and 9 pa-
tients (0.1%) in the two groups, respectively (P = 0.17), 
and chronic pancreatitis in 2 patients (<0.1%) and 
6 patients (0.1%), respectively (P = 0.18). There were 
5 cases of pancreatic cancer in the saxagliptin 
group and 12 in the placebo group (P = 0.095). 
There were no cases of fatal angioedema; nonfatal 
angioedema occurred in 8 patients in the saxa-
gliptin group and 1 in the placebo group (P = 0.04).
Discussion
In this randomized, placebo-controlled trial, the 
DPP-4 inhibitor saxagliptin neither reduced nor 
increased the risk of the primary composite end 
point of cardiovascular death, myocardial infarc-
tion, or ischemic stroke, when added to the stan-
Table 2. Prespecified Clinical End Points.*
End Point
Saxagliptin 
(N = 8280)
Placebo 
(N = 8212)
Hazard Ratio 
(95% CI) P Value
no. (%)
Cardiovascular death, myocardial infarction, or 
stroke: primary efficacy end point
613 (7.3) 609 (7.2) 1.00 (0.89–1.12) 0.99
Cardiovascular death, myocardial infarction, 
stroke, hospitalization for unstable angina, 
heart failure, or coronary revascularization: 
secondary efficacy end point
1059 (12.8) 1034 (12.4) 1.02 (0.94–1.11) 0.66
Death from any cause 420 (4.9) 378 (4.2) 1.11 (0.96–1.27) 0.15
Death from cardiovascular causes 269 (3.2) 260 (2.9) 1.03 (0.87–1.22) 0.72
Myocardial infarction 265 (3.2) 278 (3.4) 0.95 (0.80–1.12) 0.52
Ischemic stroke 157 (1.9) 141 (1.7) 1.11 (0.88–1.39) 0.38
Hospitalization for unstable angina  97 (1.2)  81 (1.0) 1.19 (0.89–1.60) 0.24
Hospitalization for heart failure 289 (3.5) 228 (2.8) 1.27 (1.07–1.51) 0.007
Hospitalization for coronary revascularization 423 (5.2) 459 (5.6) 0.91 (0.80–1.04) 0.18
Doubling of creatinine level, initiation of dialysis, 
renal transplantation, or creatinine >6.0 mg/dl 
(530 μmol/liter)
194 (2.2) 178 (2.0) 1.08 (0.88–1.32) 0.46
Hospitalization for hypoglycemia  53 (0.6)  43 (0.5) 1.22 (0.82–1.83) 0.33
* Event rates and percentages are 2-year Kaplan–Meier estimates.
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dard of care in patients at high risk for cardiovas-
cular events, thus meeting the criterion for 
noninferiority16 to placebo but not providing any 
cardioprotective benefit. Saxagliptin was associ-
ated with significantly improved glycemic con-
trol and reduced the development and progres-
sion of microalbuminuria; however, it increased 
the risk of hospitalization for heart failure and 
the risk of hypoglycemic events. Taken together, 
our findings provide data to evaluate both the 
benefits and risks of saxagliptin in patients at 
high risk for cardiovascular events.
Saxagliptin, together with several other DPP-4 
inhibitors, represents a class of oral antihyper-
glycemic agents that are approved for glycemic 
control. Pooled data from the phase 2b–3 stud-
ies of saxagliptin showed that patients treated 
with saxagliptin had a significantly lower rate of 
major adverse cardiovascular events than did 
control patients.18 Moreover, pooled analyses 
from other development programs for DPP-4 
inhibitors showed similar trends toward improved 
cardiovascular outcomes with active therapy.22,23 
The apparent discordance between the findings 
of the phase 2b–3 trials and this larger, post-
marketing trial highlights the importance of 
performing properly powered studies with ap-
propriate follow-up and formalized adjudication 
procedures to provide a full evaluation of the 
long-term risks and benefits of therapy.
There are several potential explanations for 
the finding that a median of 2 years of therapy 
with saxagliptin did not reduce the rate of is-
chemic events, despite improved glycemic in-
dexes. First, exposure to the study drug may not 
have been long enough to reverse the effects of 
years of pro-atherosclerotic processes in patients 
with a median duration of diabetes mellitus of 
more than 10 years; therefore, the study does not 
exclude the possibility of either benefit or risk 
with a longer duration of saxagliptin therapy. 
The United Kingdom Prospective Diabetes Study 
(UKPDS), for example, required 10 years of fol-
low-up after the actual intervention period was 
complete to show a beneficial effect of intense 
glucose control on reducing the risk of myocar-
dial infarction, though that study included low-
risk patients who were enrolled soon after the 
diagnosis of diabetes.6
Second, the actual difference in glycated he-
moglobin levels between the study groups was 
relatively small because additional antihypergly-
cemic therapy was prescribed at the discretion of 
the treating physician and was used more fre-
quently in the control group than in the saxa-
gliptin group. However, other studies in which 
there was greater glycemic differentiation over a 
longer period have also not individually shown 
definitive macrovascular benefit with more intense 
glycemic control,9-11 and therefore, the overall 
hypothesis that improved glycemic control will 
reduce macrovascular events remains in ques-
tion. Moreover, a large proportion of patients 
in our trial received statins, antiplatelet therapy, 
and blood-pressure–lowering agents — thera-
pies that may have mitigated the cardiovascular 
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Figure 1. Kaplan–Meier Rates of the Primary and Secondary End Points.
The primary end point (Panel A) was a composite of death from cardiovas-
cular causes, myocardial infarction, or ischemic stroke. The secondary end 
point (Panel B) was a composite of death from cardiovascular causes, myo-
cardial infarction, ischemic stroke, hospitalization for unstable angina, cor-
onary revascularization, or heart failure.
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risk and blunted potential differences between 
the study groups.21,24
The observation of a higher incidence of hos-
pitalization for heart failure among patients 
treated with saxagliptin was unexpected and 
should be considered within the context of mul-
tiple testing that may have resulted in a false 
positive result. This finding merits further inves-
tigation and needs to be confirmed in other 
ongoing studies, and a class effect should not be 
presumed.25,26 The increased risk of heart failure 
has been observed with other antihyperglycemic 
agents, including thiazolidinediones13,27 and dual 
peroxisome-proliferator–activated receptor α–γ 
agonists,15 with divergent results in trials of in-
tensive glucose management.28,29
Saxagliptin reduced the development and pro-
gression of microalbuminuria, though it is un-
clear whether the degree of change observed in 
our study would be associated with a subsequent 
decrease in cardiovascular or renal complica-
tions.30,31 We found no differences between saxa-
gliptin and placebo with respect to the prespeci-
fied adverse events of special interest, including 
acute or chronic pancreatitis. We also found no 
excess of pancreatic cancer with saxagliptin, de-
spite observational reports of a potential associa-
tion between DPP-4 inhibitors and these events.32-35
Numerous studies, even those involving pa-
tients with advanced cardiovascular disease, 
have shown that improved glycemic control re-
duces microvascular complications. Thus, there 
remains a strong clinical need for antihypergly-
cemic drugs that can improve glycemic control 
without increasing the risk of cardiovascular 
complications. Few antihyperglycemic agents have 
been evaluated as extensively as saxagliptin was 
in this trial; the findings point to likely but un-
Table 3. Safety End Points.
End Point
Saxagliptin
(N = 8280)
Placebo
(N = 8212) P Value*
no. (%)
Thrombocytopenia 55 (0.7) 65 (0.8) 0.36
Lymphocytopenia 49 (0.6) 40 (0.5) 0.40
Severe infection 590 (7.1) 576 (7.0) 0.78
Opportunistic infection 21 (0.3) 35 (0.4) 0.06
Hypersensitivity reaction 93 (1.1) 89 (1.1) 0.82
Bone fracture 241 (2.9) 240 (2.9) 1.00
Skin reaction 228 (2.8) 232 (2.8) 0.81
Renal abnormality 483 (5.8) 418 (5.1) 0.04
Any hypoglycemia† 1264 (15.3) 1104 (13.4) <0.001
Major 177 (2.1) 140 (1.7) 0.047
Minor 1172 (14.2) 1028 (12.5) 0.002
Cancer 327 (3.9) 362 (4.4) 0.15
Any liver abnormality† 55 (0.7) 67 (0.8) 0.28
AST >3× ULN 60 (0.7) 61 (0.7) 0.93
AST >10× ULN 12 (0.1) 15 (0.2) 0.57
ALT or AST >3× ULN and total bilirubin >2× ULN 13 (0.2) 23 (0.3) 0.097
Any pancreatitis† 24 (0.3) 21 (0.3) 0.77
Acute: definite or possible 22 (0.3) 16 (0.2) 0.42
Acute: definite 17 (0.2) 9 (0.1) 0.17
Acute: possible 6 (0.1) 7 (0.1) 0.79
Chronic 2 (<0.1) 6 (0.1) 0.18
* P values were calculated with the use of Fisher’s exact test. ALT denotes alanine aminotransferase, AST aspartate amino-
transferase, and ULN upper limit of the normal range.
† Patients may have had more than one type of event.
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proven benefit with respect to microvascular 
disease without adverse macrovascular outcomes. 
Together with ongoing trials of other DPP-4 in-
hibitors and novel antihyperglycemic agents, 
these data will provide a more rigorous and ro-
bust evidence base than is currently available to 
guide the future care of patients with diabetes.
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